前列腺特异性膜抗原PET/CT示踪剂在前列腺癌生化复发中的检出率:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入43项研究共5832例根治性治疗后生化复发的前列腺癌患者,评估多种PSMA PET/CT示踪剂的检出率。总体检出率为74.1%(95%CI 69.2%-78.5%),各示踪剂间无差异;PSA<0.2 ng/ml时检出率33.7%,PSA≥2.0 ng/ml时达91.7%。结论认为PSMA PET/CT在PSA较低时检出率有限但优于传统影像,且各示踪剂间无优劣之分。
要点
- 总体检出率74.1%,各PSMA示踪剂间无显著差异。
- PSA<0.2 ng/ml检出率33.7%,PSA≥2.0 ng/ml达91.7%。
- PSA倍增时间或速率不影响示踪剂间检出率差异。
核心结论
- PSMA PET/CT在生化复发前列腺癌再分期中总体检出率为74.1%(95%CI 69.2%-78.5%)。
- PSA水平越低检出率越低(<0.2 ng/ml为33.7%,0.2-0.49 ng/ml为50.0%),但仍优于胆碱PET/CT或骨扫描等传统影像。
- 目前没有一种PSMA示踪剂在网状Meta分析中优于其他示踪剂。
研究设计与样本
- 系统综述与网状Meta分析,遵循PRISMA声明,检索MEDLINE、Embase和Web of Science。
- 纳入43项回顾性或前瞻性研究,共5832例根治性前列腺切除和/或放疗后生化复发的患者。
- 评估的示踪剂包括镓-68-PSMA-11、镓-68-PSMA I&T、镓-68-THP-PSMA、铜-64-PSMA-617、氟-18-DCFPyL和氟-18-PSMA-1007。
- 采用比例Meta分析和网状Meta分析,异质性用Cochran Q和I2统计量评估,质量用QUADAS-2评估。
主要发现
- 总体检出率为74.1%(95%CI 69.2%-78.5%),各示踪剂间无差异。
- PSA<0.2 ng/ml、0.2-0.49 ng/ml、0.50-0.99 ng/ml、1.0-1.99 ng/ml和≥2.0 ng/ml亚组的检出率分别为33.7%、50.0%、62.8%、73.1%和91.7%。
- 根据PSA倍增时间或PSA速率,未发现示踪剂间检出率差异。
- 网状Meta分析未显示任何示踪剂优于其他示踪剂。
- 所有分析均存在高异质性和不一致性,纳入研究偏倚风险低。
关键数值与推荐
- 总体检出率74.1%(95%CI 69.2%-78.5%)。
- PSA<0.2 ng/ml检出率33.7%,0.2-0.49 ng/ml为50.0%,0.50-0.99 ng/ml为62.8%,1.0-1.99 ng/ml为73.1%,≥2.0 ng/ml为91.7%。
临床怎么用
- 对于根治性治疗后生化复发的前列腺癌患者,PSMA PET/CT可用于再分期,尤其PSA≥1 ng/ml时检出率较高。
- PSA<0.2 ng/ml时检出率较低(33.7%),但仍可能优于传统影像,需结合临床决策。
- 示踪剂选择上暂无优先推荐,可根据可及性选用。
局限性
- 所有分析存在高异质性和不一致性。
- 需要进一步研究明确这些影像技术的诊断性能和作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Restaging of prostate cancer in patients with biochemical recurrence after radical treatment remains a challenging clinical scenario as current imaging modalities are suboptimal. To date, prostate specific membrane antigen positron emission tomography/computerized tomography seems to represent a very promising diagnostic tool in this setting. Therefore, we evaluated the detection rate of several positron emission tomography/computerized tomography prostate specific membrane antigen based tracers in the restaging of prostate cancer in patients with biochemical recurrence. MATERIALS AND METHODS: According to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement, a systematic search was performed across MEDLINE®, Embase® and Web of Science™. PICOS (Patient, Intervention, Comparator, Outcome, Study Type), criteria consisted of P: patients with biochemical recurrence after radical prostatectomy and/or radiation therapy as primary treatment; I: studies using gallium-68-prostate specific membrane antigen-11, gallium-68-prostate specific membrane antigen inhibitor for imaging and therapy, gallium-68-trishydroxypyridinone-prostate specific membrane antigen, copper-64-prostate specific membrane antigen-617, fluorine-18-DCFPyL or fluorine-18-prostate specific membrane antigen-1007; C: no control group or positron emission tomography/computerized tomography comparative studies; O: patient specific overall detection rate; and S: retrospective/prospective studies. A meta-analysis of proportions and a network meta-analysis were performed. Heterogeneity was assessed using Cochran Q and I2 statistics. Quality was assessed by QUADAS-2 (University of Bristol, Bristol, United Kingdom). Funnel plots and Egger test were used for publication biases. RESULTS: A total of 43 studies including 5,832 patients were identified and included in the analysis. An overall detection rate of 74.1% (95% CI 69.2%-78.5%) was found, with no differences between tracers. The overall detection rates were 33.7%, 50.0%, 62.8%, 73.1% and 91.7% % in prostate specific antigen subgroups of less than 0.2 ng/ml, 0.2 to 0.49 ng/ml, 0.50 to 0.99 ng/ml, 1.0 to 1.99 ng/ml, and 2.0 ng/ml or greater, respectively. No difference between tracers was found according to prostate specific antigen doubling time or prostate specific antigen velocity. No tracer proved superior to the others through network meta-analysis. High heterogeneity and inconsistency were found across all analyses. Included studies showed a low risk of bias. CONCLUSIONS: Prostate specific membrane antigen positron emission tomography/computerized tomography for prostate cancer restaging in patients with biochemical recurrence achieves best detection rates (over 70%) if prostate specific antigen is below 1 ng/ml. At lower prostate specific antigen levels the detection rate of prostate specific membrane antigen positron emission tomography/computerized tomography is lower (33.7% for levels below 0.2 ng/ml and 50% for levels 0.2 to 0.49 ng/ml), despite being better than "older" tracers such as choline based positron emission tomography or computerized tomography/bone scintigraphy. Furthermore, no prostate specific membrane antigen tracer can be currently considered superior to others. Further studies are needed to better define the diagnostic performance and role of these imaging techniques.
引用
- Crocerossa F, Marchioni M, Novara G, et al. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis. J Urol. 2020. PMID: 32935652. doi:10.1097/JU.0000000000001369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。